
Matricelf Advances Spinal Cord Injury Trial with Loewenstein Partnership
Tel Aviv-based regenerative medicine firm Matricelf has secured approval from the Helsinki Committee and Loewenstein Rehabilitation Medical Center to begin blood collection for its spinal cord injury research. This step allows the company to identify eligible patients for a planned first-in-human study involving autologous neural tissue implants.
























